7. Bristol-Myers Squibb

Total: $222.4 million
TV: $152.2 million
Magazine: $61.5 million
Newspaper: $8.5 million
Radio: $22,200

For Bristol-Myers Squibb ($BMY), there is a rising star and a setting sun. Still on the rise--and on a potential blockbuster course--is next generation blood thinner Eliquis, which it co-markets with Pfizer ($PFE). But as of April 28, the antipsychotic Abilify, which BMS markets along with partner Otsuka, faces a cadre of generic competitors.

Overall ad spending was up for BMS last year, by 42% over 2014. Overall revenue, however, was down to $15.9 billion from $16.4 billion in 2013. While 2015 sales look to be another trough, Bristol-Myers' immunotherapy cancer drug Opdivo is predicted by analysts to make, and possibly break, a $6 billion peak in sales. That probably doesn't mean a big impact on ad spending, however, as oncology drugs are generally not targeted at mass audiences.

For more:
Bristol-Myers is counting on DTC to keep driving Eliquis growth
BMS, Pfizer pull out all the stops to give Eliquis sales a Q2 jolt
The PD-1 wave? Report says it's a $33B tsunami, with BMS surfing for first place
With Opdivo approval, Bristol-Myers arms for PD-1 battle against Merck's Keytruda

7. Bristol-Myers Squibb

Suggested Articles

Pfizer and Astellas are chasing a new nod for prostate cancer drug Xtandi, and thanks to the FDA, they might not have to wait that long.

As AZ and FibroGen have yet to submit the novel anemia drug to the U.S. regulators, national reimbursement talks are already underway in China.

Health and Human Services, hoping to resurrect a rule that would force drug prices into TV ads, appealed a judge's decision that blocked it.